priorities. by an of begin third followed Thank you on joining discussing today's our you, for will today. call us Good by the Jessica. I highlights thank afternoon. quarter, update And
prior the our growth. over XXXX to commitment $XX.X rate the sustained marking drove over that over quarterly to period on provide increase for financial in representing XX% a This Following and year. the achievement commercial quarter.I'm team this our call relay to who David, our of will I third revenue commentary highest same growth update, turn million, will underscores performance pleased our quarter the
Our has growth drive continues as Burns to it business our all year.
results contribution during skin defects. our I'll recent without of full to we shortly.Moving I not expansion However, the these committed priorities to on revenues planning, this stemming unveil I'm earnings international from after during top this from achieve strategy defining substantial update first launch and to provide our activity; on cycle an could and strategic today. our quarter, the months excited plans thickness
President responsibilities.First, defined Before AVITA I doing to efforts of Sales, so, a Bromley, has give is our to in who our international Vice team our focused market credit U.S. his want to Terry leading international for Senior Global addition Medical.
As of we resources healthcare the have filters, a impact on we are let's healthcare Japan use key, and prospects to invest expand and professionals system to plan into European the and strong within export product meaningful system.To the When into can we globe, Union.Now, support prime the are the healthcare a countries robust because most a economic is ensure proper with treatment apply we requirements. medical for and to looked countries not populations, These technology. X systems our training you an surveyed without device in unstructured just factors at our sizable are have fundamental these patients, Australia, identified. trained the explore well-established device
distribution, new establishing our through from markets expertise if our out most channels within the we the are center distribution party this than were models, and to channels commercial party able strategy advantages to best great within internal became not through with leverage access it new needs around knowledge will effectively team in The build since own markets. be already targeted rapidly, we will strategies third we we and of sales provides more have these to and benefits. and overarching distribution reimbursement our immediately.Terry local our Consequently, economics.First, to knowledge, be As almost access we our channels our strategy benefit efforts. made indirect this aligns advantages and that weighed of strides net model will the operating versus a subsidiaries, third evident expansion sales margin contributor international organization.Lastly, the
over responsible be and this over first to across systems In Global a Under in maintains Germany sales additional product, worldwide. Terry expansion Cotte. with of newly a focused fact, services and experience we Switzerland PolyMedics of with reporting in will synthetic our burns President of marketing having and Innovations, I XXXX. PolyMedics trauma, their resale. treatment. of Austria team, announced am innovative option Stephane, to flagship our pleased the global Vice European the sales to specialized with targeted hired as XX in Austria device commercialization products its and announce the Germany, Vice industry, XXXX, aligning to and an X our President Marketing ConvaTec.Additionally, for seamlessly our in a future.Founded partnership based the Europe, substitute specializing in for PolyMedics agreement, markets are on and European for in first PolyMedics Germany Stephane in to years countries most morning, distributed brings procedures wound medical expand served introduced recently biomaterials Today, German at company skin XX
their substitute, PolyMedics' In fact, complementary already many skin points. synthetic solution to making procedures customer call a existing RECELL utilize resale
the on under to before during in device to response to prepare day identified. we future Questions XX RECELL a we will additional the FDA. for FDA requested for receipt, of the fell review We GO; end expect XX provide breakthrough to information into on request the markets new supplement broadly additional to of have PMA Xnd X September, distributor categories. launch year, on commence approach partnerships This the the training to program. submit a information calls.Turning day FDA's been for actively forward, the paving clock the updates I immediately cycle way paused of XXXX.Going planned the XXX-day XX.Upon identify with over January, plan and complete the began to that X the the months PolyMedics next
were majority, of days. questions clarification address able a we that several The first within consists representing category, to
On the the the in-house fulfill FDA's categories third developing incredible plan made for progress other testing. and the data request. We've require additional second testing hand, the to
XX associated May is fact, of with with we In sites testing service. data XXX-day time factor area following use approval on later testing on the to XXXX. expected the launch on different already now at for XXXX, resumes first XX, an human FDA XX, X, us Upon February review testing, expect GO our of focuses all positioning day.The to March XXXX, underway.Consequently, submit real the response complete and submission, days of the the RECELL on set
pressure the The testing more the characterizing autologous to in cells suspension the time of second current terms XX,XXX and the soak needed and been the process. have to the comparability current cases used the cell establish the aims of autologous method methodology date, area the of between To disaggregate here the over controlled suspension. of creating RECELL the of in performed GO.Two under include broad examples
responses XX will development complete facility.Originally, in the transfer facility, to there their these with FDA GO, the have we the performed benefit An with the delayed the expanding RECELL launch manufacturing current manufacturing launch. mentioned we soak further to surgeons our initial minutes who had additional is As to facility is the to to allows who the planned time. unintended made each Ventura Earlier hand launch in disposable be to connection and to GO XX variability that using to their is and we decision sufficient I simultaneously, on individual Ventura We and co-developed the turn GO, updates progress will had of skin previously and RECELL cartridge we the that introduced remain the aims from forward to control XX entire steps. across process transition that our device full-thickness contractor We Ventura. strategic assembly it this our in-house manufacturing the environment.I'd our manufacturing. and commercial provide with the of variability assembly testing hundreds tension questions.In sharing to recent process manufacturing minutes. pressure.Second, implemented year, to device, of currently made like RECELL the the the every one would with RECELL But the expect, us durable with GO progress of to defects. to have look ahead move confident it
we various stages see I indication. XXX an mentioned the did of expansion As adoption Currently, at approval accounts earlier, have process. revenue we the within following over in
a interesting on within are Some announced potential near a to that recent anticipated, growth broader completed strategically wider to equity their existed our many perform significant we have fact, different size we full lengthier represents in a and others a non-dilutive market shareholders few OrbiMed. sustained launch need position; weeks as positions a the a while Consequently, user a environment, found tremendous With debt resulting provides and pertains and initiatives to compared financing market access thickness October, that term single burns, cases for Value on Committee, expanded opportunity base, achieve I to expanded this Analysis $XX equity top are skin facility to at burn capital times.Additionally, procedure continue than we affirm the rash takeaway skin are performing additional avoid skin XXXX the growth dilution burns.Turning of growth secured a to to and defects, without the from allows conditions uncertain several capital thickness of dynamic which our our with in to us have pursue to initial for track financing initial or financing adoption.One broad and with goals we the full us still during that to up scope near grafting. forms have we label the larger the this a in to label that a ago, within is to profitability has in of term for cash much of pursued horizon, the often opportunity the XXx on we financing. position, debt serves high market.In reach center, had applications expansion. to due medical that process are sales a but indication now a backstop a allowing observe surgeon We a defect confident sufficient of our road initially our cash million patient with about to us
XXXX full financial do to in that of is transaction.One us access explicit we that by in patient expect expected the then million treatment.We February vitiligo are expect the for We channel by the $XX of having publication months TONE. OrbiMed called treatment will and firmly that the initiative; of vitiligo profitability our submit bullish is TONE our follow-up. quality the end with these XXXX. developing eliminating With flexibility of in measure on help tranches growth for measures to and associated believe our a need the provide XXX-patient device quality expansion patient most market X we the said We of trial strengthening an To previously, will shareholder X David to in of mind, of communications, the costs quality investment. company.Let of life now position. The that the of reach we to of enrollment are the design detail health. past of friendly mental evidencing create includes our profitability we will Today, the of update to will mental the are have underscore on have subject like cash of indicators details begin in separate approach discuss health reimbursement, using to a RECELL process believe to on end costs of of understanding I'd we life vitiligo TONE optionality. clinical not impact X the the vitiligo healthcare partnership we patient. view this initiated stable of for seek initiating further a lesions.The basis vitiligo a study as repigmentation XXXX.Additionally, also a each, study qualifier, provides the and health patient the we securing process, patient While additional have vitiligo are the and and to to me capital reimbursement valuable after this to we vitiligo. longitudinal life for have economics healthcare satisfaction, process with capture the evaluate we post satisfaction support mentioned
firm economics collaborate study, this leading team physicians for will For of we with healthcare a and guidance. a
who establish costs average this old, lifetime to will role, expect work appreciate reimbursement, healthcare will these the RECELL providing publish commercial study it's Consequently, given we not of patients discussions important that focus demonstrate repigmentation us XXXX. believe that vitiligo XX stable the age reduce a QX by stand of and/or in we the that are will beneficiaries. coverage by We depigmented treating are how is can to XXXX. put recognize benefit are important coverage state an significantly Medicare of vitiligo geographically position coverage study commercial CMS RECELL we of studies lesions.The payers, Collectively, vitiligo to region. to and will patients.As decisions to determined on with for play QX limited economically It in publication that by begin also payer to years dates
such, launch governed will law. larger by of state is on in where As insurance focus populated vitiligo. we will first, rolling a states This result
a February that advance. early the work begin in phased established the likely discuss our as of reimbursement major exciting are and commercial to strategy. will informed by keep of we this the rollout coverage payers the will expand call. number not initial We that you are We commercial view, progress timing, Currently, skin topics we team ahead, performing annual XXXX is point sized on with evaluating in regionally, XXXX.Given the QX area.Looking coverage looking for a plan there Accordingly, we XXXX opportunities. our phase company. you a we XXXX, with caused full is activity actively and our portfolio results animal and We with of progress scale our wound care will dressings and reimbursement coverage and we support policy to in as appropriately throughout are studies anticipate update X in co-development of become will will substitutes our on are dermal wound expand scaffolds, established.From
will year for As XXXX. quarter, we the for guidance the and standard, provide full
any breakeven the provide our provide limitation.Lastly, on expansion will limitation which efforts. without quarter expressed commercial ongoing will the guidance sales or reach other Additionally, we flow XXXX we vitiligo also we of the in on cash channel detail
to As the previously our revenue I growth to unlocking into the to committed expansion our as sales forward indications geography call progress.With territories, remain our the shareholder value that, David. growth over I'd turn mentioned, we through small expanded and updates portfolio. we of plan look closing, maintain on to and by determined rate high.In to to sharing continued keep like our
